,0,1
0,money damage,9.0
1,flw dea,9.0
2,colombia,9.0
3,cautionary notice,9.0
4,surgery window,9.0
5,activation marker,9.0
6,visible swelling,9.0
7,mason,9.0
8,sequence peptide,9.0
9,biomarker test,9.0
10,bristol myers,9.0
11,anti pd antibody,8.875
12,medicines agency,8.8
13,bacterial vector,8.720930232558139
14,circulating serum,8.714285714285715
15,cavity pharynx,8.625
16,commercial success,8.625
17,retrospective approach,8.608695652173914
18,solid tumors,8.607142857142858
19,dose level,8.531512605042018
20,multiple function,8.515151515151516
21,control,8.5
22,reserved ruling,8.5
23,residual disease,8.5
24,lm technologytm,8.470930232558139
25,direct offering,8.458333333333334
26,lm llo,8.454263565891473
27,withholding tax,8.449350649350649
28,capital resource,8.444444444444445
29,feline lymphoma,8.419354838709678
30,cat certification procedure,8.4
31,dose escalation,8.397495631916133
32,months,8.388157894736842
33,allege count,8.384615384615385
34,dose level,8.34546609341411
35,cash flow,8.343023255813954
36,published literature,8.333333333333334
37,capital outlay,8.304093567251462
38,financial institution,8.3
39,months,8.286585365853659
40,control group,8.285714285714285
41,additional capital,8.285470085470084
42,disease progression,8.277777777777779
43,disease progression,8.277777777777779
44,profitability,8.25
45,investigational anti pd,8.243421052631579
46,cash position,8.237760097919217
47,preventative vaccine,8.228070175438598
48,occurrence rate,8.226651901070506
49,grade fatigue,8.210526315789474
50,escalation phase,8.175163398692812
51,balance sheets,8.172811059907835
52,tumor driver gene,8.166666666666666
53,retrospective approach,8.164251207729468
54,fever nausea,8.142857142857142
55,count,8.134615384615385
56,toxicity,8.125668449197862
57,obligation,8.117647058823529
58,committee membership,8.106382978723405
59,steering committee,8.106382978723405
60,intangible assets,8.09090909090909
61,year,8.077922077922079
62,disease control rate,8.055555555555555
63,month,8.04646510476819
64,spot mutation,8.043478260869566
65,common stock,8.042948038176034
66,oncology asco,8.042206966692092
67,anti tumor,8.041666666666666
68,significant cardiac hematological,8.027777777777779
69,track product,7.9875
70,oncology esmo,7.983277591973245
71,spot target,7.981818181818182
72,adverse events,7.968253968253968
73,cell immunity,7.96039603960396
74,cash flows,7.958407871198569
75,therapies cat,7.955555555555556
76,patented technology,7.947368421052632
77,month,7.944892575885007
78,cash,7.943023255813953
79,amount disgorgement,7.913461538461538
80,enrichment claim,7.909581646423751
81,expert committee,7.9063829787234035
82,income tax,7.89935064935065
83,osteosarcoma,7.898876404494382
84,disease patients,7.888888888888889
85,current standard,7.85676215856096
86,performance obligation,7.852941176470589
87,accounting policies,7.838122605363985
88,adverse event,7.817142857142858
89,security deposit,7.793406593406593
90,prior chemo,7.788856304985337
91,grade traes,7.7819548872180455
92,expanded development,7.781021897810219
93,solid tumor,7.773809523809524
94,ovarian cancer,7.773464078447068
95,biocon,7.773049645390071
96,free survival,7.772580272580273
97,anal cancer,7.765666807491903
98,manufacturing testing,7.75
99,cervical cancer,7.744172098497193
100,wa partially offset,7.715384615384615
101,hypotension,7.710526315789474
102,patent cost,7.7102130325814535
103,clinical trial,7.706941266209
104,competitive supply,7.706331045003813
105,month,7.70116435288849
106,employee payroll tax,7.698370257193787
107,based strain,7.697120708748615
108,additional claim,7.693589743589744
109,securities exchange act,7.684210526315789
110,biocon,7.6688829787234045
111,damage,7.666666666666667
112,aged dog,7.666666666666667
113,balance sheet,7.659824046920821
114,balance sheet arrangements,7.659824046920821
115,multiple construct,7.658008658008658
116,liability level inputs,7.651544401544402
117,modification,7.64367816091954
118,stable disease,7.621212121212121
119,sponsored ind,7.621212121212121
120,price,7.620238095238095
121,early closure,7.618390804597702
122,determined fee,7.608391608391608
123,cancer program,7.608117676728487
124,scientific research,7.606201550387597
125,trial program,7.602632876186325
126,maa wa driven,7.6
127,radiotherapy ccrt,7.6
128,salary,7.587912087912088
129,lease rate,7.584967320261438
130,complete response,7.574937343358395
131,exercise price,7.571296296296296
132,exercise price,7.571296296296296
133,tumor model,7.566666666666666
134,average number,7.560975609756097
135,future cash,7.553549571603428
136,line basis,7.545112781954887
137,liquid investment,7.541062801932367
138,net income,7.538461538461538
139,company,7.536891679748822
140,pembrolizumab merck,7.5285714285714285
141,primary endpoint,7.525
142,metastatic disease,7.521645021645021
143,consumption,7.516129032258064
144,art manufacturing facility,7.5
145,common stock,7.497493492721489
146,operational cost,7.497300944669366
147,free survival,7.494802494802496
148,equivalent concentration,7.480954290296712
149,related symptom,7.480952380952381
150,clinical trial,7.473717943876768
151,kcm,7.464475431606905
152,plaintiff,7.461538461538462
153,conditional power,7.461538461538462
154,note thereto,7.454545454545455
155,pembrolizumab adxs,7.450996677740864
156,amount,7.447398190045249
157,synonymous mutation,7.443478260869565
158,square foot,7.441798941798941
159,general allegation,7.427380952380952
160,chemotherapy regimen,7.426655348047539
161,regulatory incentive,7.422932330827068
162,design,7.415576323987539
163,data,7.408730158730159
164,month survival,7.406955858679996
165,llo technology,7.401631986944105
166,patent cash,7.387666112956811
167,recommended combination,7.386274509803922
168,stock representing share,7.382476957159919
169,states department,7.37948717948718
170,upfront fee,7.368131868131869
171,month survival rate,7.362511414235552
172,llo immunotherapy,7.3614800607368345
173,tumor burden,7.359649122807017
174,patient dataset,7.358904109589041
175,significant unmet medical,7.3529526029526036
176,escalation portion,7.332941176470589
177,neck cancer,7.327148288973384
178,cash settlement provision,7.322014852452609
179,conditional licensure,7.319875776397515
180,stock option,7.3096147048427005
181,impairment model,7.28888888888889
182,measurement,7.284153005464481
183,clinical study,7.281252149982801
184,infusion,7.278735632183908
185,axalimogene filolisbac,7.278735632183908
186,common share,7.278645001874037
187,lm technology,7.2682986536107705
188,cervical cancer,7.267981622306717
189,drug controller general,7.265977443609022
190,regulatory opportunity,7.265037593984963
191,clinical trial,7.251385710653445
192,advancement entail risk,7.249197860962566
193,klebsiella lung infection,7.241830065359478
194,complete response,7.233244553389744
195,osteosarcoma specialist,7.214665878178593
196,front payment,7.204545454545455
197,product candidate,7.1947368421052635
198,biologics research,7.190816935002982
199,tolerated dose,7.186274509803921
200,specific performance,7.184210526315789
201,significant loss,7.180555555555555
202,clinical site,7.179808495597969
203,worldwide license,7.177166224580018
204,concurrent chemotherapy,7.17255163224517
205,poor outcome,7.1692307692307695
206,tumor activity,7.168939393939393
207,epitopes,7.148595805190189
208,cervical cancer,7.146769501094596
209,project milestone,7.142978723404255
210,fusion protein,7.142857142857142
211,facility cost,7.1387844611528815
212,oncology,7.1319809512029195
213,axalimogene,7.128735632183908
214,reporting date,7.121621621621622
215,targeted therapy,7.109243697478991
216,gog ha successfully,7.108743644634734
217,common stock,7.107464167208292
218,trial,7.1054698457223
219,share settlement,7.1009761857547185
220,fda ha cleared,7.1001100110011
221,stock share,7.090756803116273
222,conditional licensure,7.09073359073359
223,unknown factor,7.089983022071308
224,safety profile,7.086021505376344
225,equity equity warrant,7.083461736004109
226,phase study,7.083006535947713
227,company shareholder,7.082346225203368
228,company,7.081446135194367
229,patent range,7.08107333842628
230,cerv,7.075
231,diluted earnings,7.0576519916142555
232,tabular disclosure,7.057239057239057
233,clinical data,7.056182121971596
234,development program liquidity,7.054491285565321
235,common traes,7.0428663121217685
236,cancer pipeline development,7.028170186783603
237,annual period,7.027436270574066
238,represented share,7.021415803063406
239,bevacizumab treatment,7.01782531194296
240,past employee,7.00390682588825
241,treatment regimen,7.000653594771242
242,kcm,7.0
243,credit loss,6.995983352690669
244,private equity,6.995337995337995
245,stock,6.990683229813665
246,based compensation,6.990683229813664
247,stock set,6.990316459228666
248,lm technology,6.9840881272949815
249,anal cancer,6.977788019613114
250,development program,6.97495912182263
251,accounting pronouncement,6.96867816091954
252,duty claim,6.962213225371119
253,treatment regimen,6.961227071473751
254,fully funded exclusively,6.952380952380952
255,share,6.941748158879632
256,net loss,6.941239316239316
257,tumor response,6.940545808966861
258,effect,6.936697653829128
259,base salary,6.936697653829128
260,cervical cancer,6.934648288973384
261,promissory note,6.930555555555555
262,actual result,6.93
263,multiple target,6.925541125541125
264,potential application,6.924851680949242
265,price,6.91463963963964
266,compensation cost,6.911403508771929
267,liability warrant,6.902755055297428
268,additional capital,6.9008547008547
269,normal recurring accrual,6.897727272727273
270,capitalized cost,6.894736842105264
271,cell response,6.890220601007469
272,drug development pipeline,6.886285055704956
273,gog wa presented,6.885963382737576
274,application patent application,6.872386759581882
275,spending cash,6.865642303433001
276,granted exclusive worldwide,6.865384615384615
277,canine osteosarcoma,6.8627856986496045
278,trial collaboration,6.858988049834732
279,asset patent,6.856385281385281
280,accounting standards,6.855799373040751
281,future,6.853383458646617
282,credit loss,6.853126209833527
283,adequate safety,6.852688172043011
284,financial statement,6.851671732522796
285,development tax credit,6.845006693502331
286,lessor,6.83415435139573
287,repeat cycle,6.831475287997026
288,cash cash,6.823977546110665
289,account balance,6.808285404684504
290,clinically research,6.8062015503875966
291,stock option plan,6.803517143867092
292,virus challenges,6.795121951219512
293,increase wa attributable,6.792813321647677
294,protocol design,6.788888888888889
295,enrollment,6.787100103199174
296,collaboration,6.78110661268556
297,promissory note,6.777777777777778
298,cfu dose level,6.775415044066406
299,administrative expenses,6.773645320197044
300,research organization,6.766669386644907
301,wa,6.757190635451505
302,early adoption,6.756438778129546
303,axalimogene filolisbac,6.75095785440613
304,service period,6.748128182090445
305,adverse effect,6.746031746031747
306,significant investment,6.74405425492382
307,quarter,6.742857142857143
308,disease stage,6.737798546209761
309,nrg oncology,6.732265446224257
310,conducting gog,6.7308558558558556
311,enrollment,6.720725727361883
312,significant revenue,6.7206152433425155
313,warrant liability,6.717040769583143
314,neo,6.716185511895215
315,mutation hotspot,6.710144927536232
316,cancer immunotherapy,6.7099203393743005
317,trial expense,6.7060865653543
318,tax,6.701731601731602
319,disease results,6.7
320,arrangement fee,6.693846153846154
321,target cell,6.692214221422143
322,shareholder equity section,6.6818181818181825
323,instruments warrants,6.681818181818182
324,financial statement,6.681342062193126
325,safety endpoint,6.677688172043011
326,seer database,6.66907166907167
327,cancer recurrence,6.667981622306717
328,approximately million primarily,6.664021164021165
329,tumor target,6.656177156177156
330,stock option,6.656159420289856
331,earnings process,6.655665566556657
332,cervical head,6.655578521531524
333,drug,6.651691729323307
334,approximately million attributable,6.647537647537648
335,targeted change,6.646825396825397
336,future payment,6.645841001104159
337,settlement,6.644117647058824
338,holding period,6.642619311875693
339,accounting standard,6.636006507678267
340,cerv study,6.63578431372549
341,adjuvant axalimogene,6.632183908045977
342,conversion price,6.622222222222222
343,common public,6.619247825345387
344,bsm shares,6.605692599620493
345,based immunotherapy,6.6043372035939765
346,registrational opportunity,6.60233918128655
347,maturity investment purchase,6.592650103519668
348,financial information,6.591666666666667
349,fasb issued asu,6.588325652841782
350,maturity date,6.585907335907336
351,net loss,6.5853071128494856
352,share,6.584700444689061
353,contract research organization,6.57953488372093
354,cell carcinoma,6.571212582551999
355,patient experiencing mild,6.558904109589041
356,ongoing adxs,6.547958539408608
357,cash amount,6.54494633273703
358,loss approach,6.539251207729468
359,notification,6.536891679748822
360,cash compensation expense,6.5366129994036966
361,approximately million wa,6.533251933251933
362,india dcgi accepted,6.529644268774703
363,supply cost research,6.512532595391411
364,metastatic disease,6.512121212121212
365,development payment,6.506035188612984
366,asia,6.5
367,hpv infection,6.492194674012856
368,year beginning,6.491525019098548
369,cancer society,6.491265936032208
370,primary objective,6.477613361024575
371,year,6.475771540287669
372,stock option award,6.4748823640127995
373,tenant improvement allowance,6.471861471861471
374,cervical cancer,6.467981622306717
375,commitment,6.46574074074074
376,cancer,6.459269501094597
377,milestone,6.455652173913043
378,data,6.4531746031746025
379,stage study fawcett,6.4430273043796955
380,market price purchase,6.433986175115207
381,stage population,6.432242990654205
382,activity advaxis,6.413563049853372
383,employment agreement,6.410671936758893
384,palliative radiation,6.408333333333333
385,amended lease,6.383643739627512
386,chemoradiation treatment,6.370098039215686
387,patient,6.358904109589041
388,cancer immunotherapy agent,6.354364783818745
389,efficacy endpoint,6.341269841269841
390,research,6.334937182571505
391,adverse event,6.333271889400921
392,fda feedback,6.330555555555556
393,revenue arrangement,6.3261707988980715
394,united states,6.321286121286121
395,obligation table,6.319607843137255
396,result,6.318888888888889
397,additional advaxis,6.311839773130096
398,future payment,6.306376118161015
399,neck cancer,6.303892475019896
400,study,6.302450980392157
401,public offering,6.297699849170438
402,product license application,6.286070227081582
403,disclosure,6.282587257707293
404,company,6.281446135194368
405,balance sheet date,6.281445668542443
406,issuance equity warrant,6.280431432973806
407,risk factor,6.27192082111437
408,survival time,6.27183705444575
409,laboratory space,6.269230769230769
410,neck cancer,6.268947230772326
411,early data,6.25675059295749
412,calendar year end,6.2564935064935066
413,stendhal agreement,6.252380952380952
414,expected payment,6.241649526943645
415,financial statement,6.237386018237082
416,osteosarcoma adxs,6.233331728851787
417,infusion patient,6.230116230801162
418,substantive effort,6.229166666666666
419,related grade,6.222291021671827
420,study cohort,6.222005435837701
421,investigational immunotherapy,6.21313754747694
422,stage,6.210978622838113
423,action,6.203571428571428
424,net sale,6.198407775020678
425,construct,6.192375988085692
426,share,6.190056275608803
427,based award,6.184406173536608
428,lease standard,6.163850874265027
429,credit risk support,6.149523581230898
430,axalimogene filolisbac,6.144120247568523
431,research,6.1395348837209305
432,osteosarcoma adxs,6.1263707780877805
433,revenue,6.102361275088548
434,fda,6.1001100110010995
435,safety data,6.091973886328725
436,liability liability,6.090013742556115
437,loss model,6.082189542483659
438,neoepitope sequence,6.071428571428571
439,equity instrument,6.054583098061359
440,research collaboration,6.051815585475317
441,neck cancer,6.0414340032590985
442,generally measured based,6.027472527472527
443,osteosarcoma adxs,6.022805413062314
444,contractual commitments,6.00909090909091
445,safety,5.982991202346041
446,hpv,5.965067734514783
447,milestone payment,5.964545454545455
448,study stage,5.963495140637005
449,october patients,5.961952026468156
450,companion dog,5.942528735632184
451,raised approximately million,5.933251933251933
452,mine,5.923469387755102
453,company,5.9147794685277
454,hpv adxs,5.882033555301806
455,treatment,5.866310160427807
456,business plan,5.860823332042845
457,positive head,5.8505518071557905
458,significant revenue,5.815853338580611
459,lung cancer,5.800089465443972
460,company,5.795731849480082
461,estimate impact,5.794444444444444
462,lung cancer case,5.7834227987773055
463,collectability account balance,5.76384096024006
464,nature amount timing,5.761414754835808
465,estimate wa made,5.754901960784314
466,stendhal agreement,5.75021645021645
467,volatility input,5.7492572786690435
468,guidance,5.745454545454545
469,treatment option,5.741494435612083
470,operation support,5.7342342342342345
471,market data,5.7304147465437785
472,world summary report,5.727777777777778
473,increase wa due,5.721384750219105
474,efficacy criterion,5.711843711843713
475,data,5.708118731363513
476,advaxis study,5.691305405536904
477,combination phase,5.663695090439277
478,share,5.649216573721319
479,long term,5.647688060731539
480,keytruda pembrolizumab,5.642857142857143
481,patient initially enrolled,5.6351278858128175
482,radiation treatment,5.620098039215686
483,developed adxs dual,5.586420077870146
484,business plan summary,5.585691056910569
485,approximately million due,5.576109076109076
486,tme,5.555555555555555
487,dose level,5.531512605042017
488,revenue,5.529729145313561
489,company,5.528344671201814
490,significantly change,5.523136427566808
491,unjust enrichment,5.473684210526316
492,lm llo,5.454263565891473
493,primarily attributable,5.445054945054945
494,capital resource,5.444444444444445
495,company,5.425196135194367
496,dtllo,5.396396396396397
497,revenue,5.396395811980227
498,support payment,5.396119381413499
499,disease free,5.346153846153847
500,effective january,5.344047619047619
501,amortization expense,5.341835357624831
502,part defendant motion,5.293298207042948
503,program liquidity,5.273469387755102
504,month,5.258307210031348
505,month,5.258307210031348
506,final result,5.253529411764706
507,interim analysis,5.238333333333333
508,fusion protein,5.166666666666666
509,prior line,5.087557603686636
510,tax credit,5.063984795692113
511,common stock,5.042948038176034
512,solid tumor,5.023809523809524
513,infusion,5.016666666666667
514,shareholder equity,5.015151515151516
515,additional space,5.007692307692308
516,cancer,4.997148288973384
517,common shareholder,4.990576496674057
518,study lts,4.9830065359477125
519,facility cost,4.978070175438596
520,rent expense,4.955494505494506
521,early closure,4.951724137931034
522,clinical site,4.9490392648287385
523,diluted earnings,4.944444444444445
524,nrg oncology,4.94279176201373
525,quoted price,4.941666666666666
526,repeat cycle,4.94017094017094
527,cervical cancer,4.934648288973384
528,outstanding warrant,4.929782082324455
529,clinical trial,4.929163488431223
530,secondary endpoint,4.928571428571429
531,equity offering,4.928030303030303
532,primary endpoint,4.925
533,upfront payment,4.9188311688311686
534,administrative organization,4.915
535,infectious disease,4.9
536,anti dilutive,4.875
537,cerv,4.875
538,palliative radiation,4.875
539,current liability,4.8677098150782365
540,stock option,4.864492753623189
541,performance obligation,4.852941176470589
542,employee withholding,4.849019607843137
543,customer contract,4.833333333333334
544,unmet medical,4.825174825174825
545,patent cash,4.825166112956811
546,early adoption,4.820954907161804
547,year,4.814764183185236
548,cash,4.797568710359409
549,investigational site,4.796992481203008
550,primary objective,4.79537037037037
551,private offering,4.791666666666667
552,compensation,4.791666666666666
553,earned provided,4.789772727272727
554,grade traes,4.7819548872180455
555,capital resources,4.777777777777778
556,cardiac toxicity,4.772727272727273
557,tumor,4.766666666666667
558,symptom,4.766666666666667
559,anal cancer,4.765666807491902
560,license fee,4.757294429708223
561,approach,4.751552795031056
562,european society,4.75
563,adverse effect,4.746031746031746
564,earnings,4.732905982905983
565,trial,4.730917874396136
566,funded primarily,4.730769230769231
567,cash balance,4.730120030007502
568,seer database,4.7272727272727275
569,cytokine release,4.714285714285714
570,accounting model,4.710344827586207
571,significant advancement,4.704248366013072
572,survival rate,4.7042042042042045
573,patient advaxis,4.702437422823892
574,employee tax,4.698370257193787
575,common cancer,4.692270240192896
576,compensation,4.683333333333334
577,ongoing trial,4.677926421404682
578,patent application,4.67726480836237
579,lead program,4.673469387755102
580,lm technology,4.668298653610771
581,burden inconvenience,4.666666666666666
582,shares,4.664516129032258
583,balance sheet,4.659824046920821
584,month starting,4.658307210031348
585,twelve month,4.658307210031348
586,common grade,4.655648267008987
587,attorney fee,4.653846153846153
588,professional fee,4.653846153846153
589,diluted loss,4.652777777777778
590,cancer,4.6471482889733835
591,therapeutic improvement,4.646464646464646
592,modification accounting,4.64367816091954
593,full year,4.633477633477633
594,multiple adjuvant,4.618599791013584
595,revenue,4.613787116328053
596,equity warrant,4.613764766307139
597,short period,4.613207547169811
598,period,4.613207547169811
599,equity purchase,4.612554112554113
600,squamous carcinoma,4.610816542948038
601,significant risk,4.600505050505051
602,lung cancer,4.600089465443972
603,wa shown,4.6
604,achievability,4.6
605,wa converted,4.6
606,wa recorded,4.6
607,wa assessed,4.6
608,wa received,4.6
609,basis,4.598684210526316
610,stock options,4.5978260869565215
611,cash income,4.593023255813954
612,disclosure claim,4.584045584045584
613,actual amount,4.580128205128205
614,complete response,4.574937343358396
615,line journal,4.571428571428571
616,opportunity trial,4.566590389016018
617,interest rate,4.555555555555555
618,promissory note,4.555555555555555
619,highly immunogenic,4.555555555555555
620,additional share,4.555501072632547
621,contractual obligation,4.552941176470588
622,accrued expense,4.546153846153846
623,ha gained,4.544554455445544
624,wa approximately,4.541798941798942
625,successfully escalated,4.541666666666666
626,net income,4.538461538461538
627,preliminary data,4.535714285714286
628,axalimogene,4.528735632183908
629,fiduciary duty,4.526315789473684
630,increased expression,4.526315789473684
631,compensation committee,4.523049645390071
632,patent licensing,4.522142857142857
633,condensed statements,4.519047619047619
634,circumstance,4.517543859649123
635,multiple pathway,4.515151515151516
636,additional financing,4.507692307692308
637,embedded derivative,4.5
638,partial ruling,4.5
639,leased space,4.5
640,rare disease,4.5
641,disease,4.5
642,performance revenues,4.5
643,ind application,4.498152254249815
644,annual period,4.496186270574066
645,previously enrolled,4.495475113122172
646,design,4.4941176470588236
647,common share,4.492930716159751
648,credit risk,4.487361419068736
649,date,4.484721995507155
650,patent attorney,4.482142857142858
651,financial instruments,4.4818181818181815
652,cash,4.480954290296712
653,supply,4.478260869565217
654,supply chain,4.478260869565217
655,past employee,4.477591036414566
656,income,4.477272727272727
657,oral agreement,4.470454545454546
658,clarity,4.466666666666667
659,original maturity,4.464285714285714
660,court,4.461538461538462
661,grade,4.460526315789474
662,mortality,4.458333333333334
663,worldwide histologically,4.458333333333334
664,neoepitopes,4.454545454545455
665,development program,4.454491285565322
666,immunotherapy,4.451770950290905
667,maturity investment,4.449792960662526
668,treatment regimen,4.4450980392156865
669,mutation,4.443478260869565
670,net loss,4.441239316239316
671,warrant exercise,4.440364092906465
672,profit organization,4.4399999999999995
673,ongoing effort,4.435897435897436
674,tax,4.435064935064935
675,related cancers,4.433333333333334
676,metastatic squamous,4.431633407243163
677,ind activity,4.430303030303031
678,account,4.421188630490956
679,drug candidate,4.417763157894736
680,complaint,4.416666666666667
681,product licensure,4.416071428571429
682,related disclosure,4.4148148148148145
683,credit losses,4.414634146341463
684,equity plan,4.408721359940872
685,drug ind,4.40829346092504
686,interim period,4.404874213836478
687,partial response,4.4035087719298245
688,lease existing,4.393048128342246
689,median follow,4.388888888888889
690,primary standard,4.387025316455696
691,commercial milestone,4.385
692,global biopharma,4.384615384615385
693,annual rent,4.382978723404255
694,hold exclusive,4.3820512820512825
695,united states,4.37948717948718
696,convertible debt,4.375
697,successfully manufacture,4.375
698,intangible asset,4.374242424242424
699,transition approach,4.373401534526854
700,leases,4.366666666666667
701,cell response,4.363904811533785
702,existing law,4.363636363636363
703,study wa,4.360784313725491
704,milestone,4.36
705,revenue,4.359504132231405
706,occurrence,4.357142857142858
707,effective beginning,4.35625
708,cash investing,4.343023255813954
709,cash equivalents,4.343023255813954
710,related risk,4.33939393939394
711,data,4.339285714285714
712,full term,4.338164251207729
713,remaining period,4.335429769392034
714,vaccine,4.333333333333334
715,missing element,4.333333333333334
716,neck cancer,4.327148288973384
717,clinical research,4.326669386644907
718,contractual commitment,4.325
719,primary osteosarcoma,4.323876404494381
720,supply agreement,4.3237154150197625
721,share price,4.322808764940239
722,phase,4.322222222222223
723,canine osteosarcoma,4.3182312432040595
724,human papillomavirus,4.315789473684211
725,analyzed including,4.315789473684211
726,employee,4.315686274509804
727,accounting pronouncements,4.310344827586206
728,aratana ha,4.308190819081908
729,study ha,4.305338769171035
730,numerous risk,4.303496503496504
731,clinical development,4.301489734067529
732,product candidate,4.3
733,exercise,4.296296296296296
734,positive outcome,4.295546558704453
735,initial application,4.295121951219512
736,american association,4.294117647058823
737,market price,4.291129032258064
738,net book,4.288461538461538
739,clinical hold,4.287134502923976
740,measure,4.285714285714286
741,stage,4.282242990654206
742,clinical study,4.2812521499828
743,adxs dual,4.278727770177839
744,exit price,4.275
745,generally consistent,4.273504273504273
746,high risk,4.272727272727273
747,accounting standard,4.272370144041903
748,investment security,4.271221532091097
749,remains ongoing,4.269230769230769
750,related note,4.266666666666667
751,related information,4.266666666666667
752,external collaboration,4.2631578947368425
753,collaboration agreements,4.2631578947368425
754,net basis,4.262145748987854
755,prior treatment,4.261227071473751
756,month property,4.258307210031348
757,administrative expense,4.251923076923077
758,billed directly,4.25
759,interest income,4.25
760,financial asset,4.25
761,neoantigens,4.25
762,prostate cancer,4.247148288973384
763,cancer death,4.247148288973384
764,cancer indication,4.247148288973384
765,common type,4.245121951219512
766,american society,4.2441176470588236
767,annual report,4.244089834515366
768,annual meeting,4.240121580547113
769,bsm exercise,4.237472766884531
770,larger range,4.235294117647059
771,smaller range,4.235294117647059
772,disease recurrence,4.233333333333333
773,combination regimen,4.233333333333333
774,normal cell,4.233123312331234
775,aratana,4.2303030303030305
776,global agreement,4.23006993006993
777,standard related,4.228691983122363
778,amortized cost,4.228070175438596
779,benefit cost,4.228070175438596
780,internal cost,4.228070175438596
781,commenced enrollment,4.226315789473684
782,criterion,4.222222222222222
783,discontinuation criterion,4.222222222222222
784,factor,4.218637992831542
785,human osteosarcoma,4.214665878178593
786,provision,4.214285714285714
787,cisplatin chemotherapy,4.210526315789474
788,grade trae,4.210526315789474
789,award,4.21038961038961
790,period,4.209981740718199
791,stock award,4.208215697346132
792,payment,4.204545454545455
793,hpv challenges,4.203305785123967
794,significantly improve,4.2
795,significantly prolong,4.2
796,equipment construction,4.2
797,inactive agent,4.2
798,significantly contribute,4.2
799,protein antigen,4.2
800,radiation therapy,4.198529411764706
801,service,4.197420634920634
802,revenue,4.192837465564739
803,purchase share,4.190665907797381
804,gog foundation,4.1891891891891895
805,gog comprise,4.1891891891891895
806,final version,4.1764705882352935
807,cash bonus,4.176356589147287
808,additional step,4.174358974358975
809,grade event,4.170526315789473
810,primary treatment,4.170098039215686
811,poor outcome,4.169230769230769
812,tumor microenvironment,4.166666666666666
813,tumor shrinkage,4.166666666666666
814,effort,4.166666666666666
815,protocol,4.166666666666666
816,conversion price,4.163888888888889
817,approved general,4.160714285714286
818,operating activity,4.16060606060606
819,cancer immunotherapy,4.154364783818745
820,sustained loss,4.152777777777778
821,market activity,4.143401759530792
822,purchase,4.142857142857142
823,greater proportion,4.142857142857142
824,effort basis,4.140350877192982
825,company stock,4.134717766705345
826,rsu activity,4.127272727272727
827,activity,4.127272727272727
828,financing activity,4.127272727272727
829,startup activity,4.127272727272727
830,award,4.1265186426476745
831,cash expense,4.1199463327370305
832,liability,4.117040769583142
833,warrant liability,4.117040769583142
834,contract term,4.115942028985508
835,extended period,4.113207547169811
836,period,4.113207547169811
837,collaborative licensing,4.111428571428572
838,quarterly report,4.111111111111111
839,foxp,4.107142857142858
840,license manufacture,4.103448275862069
841,adjuvant setting,4.103448275862069
842,adjuvant molecule,4.103448275862069
843,phase development,4.103244120032441
844,information,4.096774193548387
845,share share,4.095617529880478
846,leasehold improvement,4.090909090909091
847,factor,4.089983022071308
848,complete cohort,4.088095238095238
849,increased number,4.087291399229782
850,safety profile,4.086021505376344
851,phase study,4.083006535947712
852,company,4.081446135194367
853,equity award,4.08008658008658
854,increase wa,4.078527607361963
855,footnote required,4.076923076923077
856,relationship,4.076923076923077
857,ongoing research,4.075432319618367
858,conducted exclusively,4.075187969924812
859,risk factors,4.072727272727272
860,collaborative arrangement,4.071428571428571
861,asu ha,4.068363979255068
862,financial statement,4.06595744680851
863,recently issued,4.064516129032258
864,potential vaccine,4.063063063063064
865,operating lease,4.0627450980392155
866,deemed substantive,4.0625
867,hpv worldwide,4.0616391184573
868,hpv,4.0578512396694215
869,cancer adxs,4.055287823857105
870,adxs neo,4.049518845228548
871,cash proceeds,4.04890560875513
872,share profit,4.047808764940239
873,cancer type,4.047148288973384
874,action,4.042857142857143
875,party,4.041666666666666
876,financial condition,4.04074074074074
877,major family,4.03921568627451
878,persistent recurrent,4.031746031746032
879,expansion phase,4.030555555555556
880,adxs psa,4.030361757105943
881,enrollment,4.026315789473684
882,approximately year,4.01972101972102
883,advantageous market,4.016129032258064
884,cost,4.013784461152882
885,update provide,4.012121212121212
886,treatment option,4.011764705882353
887,development cost,4.009092073248816
888,significant portion,4.007777777777777
889,significant increase,4.006305385139741
890,cost,4.005847953216374
891,company,4.003558346415489
892,accompanying note,4.0
893,supplemental disclosures,4.0
894,financing activities,4.0
895,immune system,4.0
896,actively engaged,4.0
897,internal capability,4.0
898,scale back,4.0
899,adjustment,4.0
900,necessarily indicative,4.0
901,ultimately vest,4.0
902,practical expedients,4.0
903,unusual items,4.0
904,altogether removing,4.0
905,extraordinary item,4.0
906,equipment,4.0
907,voluntary election,4.0
908,president gregory,4.0
909,ensure reliable,4.0
910,acceptance accessibility,4.0
911,responded readily,4.0
912,independent international,4.0
913,gynecologic malignancy,4.0
914,scchns,4.0
915,mucosal,4.0
916,increasing incidence,4.0
917,surveillance epidemiology,4.0
918,mount sinai,4.0
919,baylor college,4.0
920,peripheral blood,4.0
921,taiwan china,4.0
922,expression,4.0
923,larger breed,4.0
924,frequently employed,4.0
925,acvim forum,4.0
926,progesterone,4.0
927,conventional chemotherapeutic,4.0
928,marketplace,4.0
929,accumulated deficit,4.0
930,variable interest,4.0
931,hedging,4.0
932,vigorously larkin,4.0
933,mg kg,4.0
934,information,4.0
935,princeton nj,4.0
936,separate unit,4.0
937,president,4.0
938,curative intent,4.0
939,key predictor,4.0
940,cmc information,4.0
941,incidence,4.0
942,large payload,4.0
943,parker institute,4.0
944,detoxified listeriolysin,4.0
945,arrangement qualifies,4.0
946,reward dependent,4.0
947,profit sharing,4.0
948,output,4.0
949,plaintiffs counsel,4.0
950,opdivo nivolumab,4.0
951,remains open,4.0
952,single immunotherapy,3.998125585754452
953,fiscal period,3.995560488346282
954,net proceeds,3.994343891402715
955,future development,3.991548213599693
956,gog results,3.9891891891891893
957,table,3.988888888888889
958,investment,3.9855072463768115
959,substantial investment,3.9855072463768115
960,contractual term,3.982608695652174
961,ha met,3.9820544554455446
962,target neoepitopes,3.981818181818182
963,dog accounting,3.9770114942528734
964,doubtful account,3.9767441860465116
965,prospective based,3.9761904761904763
966,extended based,3.9761904761904763
967,hierarchy,3.9761904761904763
968,accelerated based,3.9761904761904763
969,volatility,3.973856209150327
970,regulatory approval,3.973809523809524
971,gross basis,3.973684210526316
972,liability,3.972972972972973
973,drug approval,3.9719298245614034
974,tumor type,3.966666666666667
975,milestone payment,3.964545454545455
976,accumulated data,3.9642857142857144
977,standard amends,3.962025316455696
978,cell infiltration,3.9603960396039604
979,dendritic cell,3.9603960396039604
980,cancerous cell,3.9603960396039604
981,fiscal year,3.9602750190985483
982,operations,3.9602122015915118
983,exchange price,3.9592105263157893
984,grade treatment,3.95562435500516
985,historical experience,3.9523809523809526
986,initially diagnosed,3.9517045454545454
987,corporate asset,3.95
988,identical asset,3.95
989,similar asset,3.95
990,gog study,3.949973502914679
991,license agreement,3.948902821316614
992,development effort,3.9476885644768855
993,platform technology,3.947368421052632
994,technology royalties,3.947368421052632
995,licensed technology,3.947368421052632
996,proprietary technology,3.947368421052632
997,treatment,3.9450980392156865
998,october,3.942403917811136
999,sublicense fee,3.9395604395604398
1000,final milestone,3.936470588235294
1001,waste claim,3.9358974358974357
1002,nominal defendant,3.935483870967742
1003,individual defendant,3.935483870967742
1004,approximately million,3.9332519332519333
1005,legal cost,3.9317738791423
1006,axal,3.928125
1007,kcm,3.9275362318840576
1008,study protocol,3.9274509803921567
1009,adjuvant therapy,3.926977687626775
1010,business plan,3.9190243902439024
1011,development expenses,3.9189529322929775
1012,october,3.913978494623656
1013,recorded amount,3.9134615384615383
1014,amendment,3.9134125636672326
1015,development activity,3.9082946250829464
1016,additional country,3.9076923076923076
1017,personalized immunotherapy,3.907216494845361
1018,precision immunotherapy,3.907216494845361
1019,commitments,3.9
1020,decade osteosarcoma,3.898876404494382
1021,pathologic effect,3.888888888888889
1022,pennsylvania school,3.888888888888889
1023,development,3.8881647549530762
1024,potential opportunity,3.887624466571835
1025,patient increased,3.885219899062725
1026,market approval,3.882795698924731
1027,accounting estimate,3.8770114942528737
1028,office lease,3.8755656108597285
1029,financing,3.875
1030,multiple patient,3.8740556247405564
1031,systemic toxicity,3.872727272727273
1032,discovery development,3.87193098871931
1033,preclinical collaboration,3.8673245614035086
1034,payment,3.8667076167076164
1035,additional patient,3.8665964172813485
1036,study drug,3.866047471620227
1037,annual increase,3.8615063307662183
1038,initial study,3.8607843137254902
1039,revenue,3.8595041322314048
1040,adjuvant treatment,3.8485463150777552
1041,amended complaint,3.8484848484848486
1042,corporate office,3.8461538461538463
1043,pending investigation,3.8455882352941178
1044,consulting agreement,3.8454545454545457
1045,alleged agreement,3.8454545454545457
1046,tentative agreement,3.8454545454545457
1047,data,3.8392857142857144
1048,remaining award,3.832611832611833
1049,company measure,3.822605965463108
1050,adequate follow,3.8222222222222224
1051,cash increase,3.8215508631759167
1052,completed including,3.8157894736842106
1053,metastatic hpv,3.815426997245179
1054,moderate grade,3.810526315789474
1055,systemic chemotherapy,3.810526315789474
1056,operating expense,3.81025641025641
1057,share,3.809713526845001
1058,adxs,3.808139534883721
1059,result,3.8049999999999997
1060,valuable insight,3.8
1061,contingent arrangement,3.8
1062,agreement,3.797835497835498
1063,stendhal agreement,3.797835497835498
1064,estimate,3.7974358974358973
1065,neck,3.7942857142857145
1066,market participant,3.793906810035842
1067,court,3.791666666666667
1068,future grant,3.7894736842105265
1069,efficacy population,3.787698412698413
1070,term,3.782608695652174
1071,development arm,3.781021897810219
1072,development initiative,3.781021897810219
1073,development manufacture,3.781021897810219
1074,amgen,3.78018018018018
1075,delaware court,3.7777777777777777
1076,excellence,3.7777777777777777
1077,participant exposure,3.7777777777777777
1078,potential share,3.777538494669969
1079,depreciation expense,3.776923076923077
1080,expense category,3.776923076923077
1081,incur expense,3.776923076923077
1082,internal expense,3.776923076923077
1083,collaboration agreement,3.7752791068580542
1084,cash,3.7715946843853825
1085,product development,3.768521897810219
1086,company,3.767660910518053
1087,table,3.7666666666666666
1088,table,3.7666666666666666
1089,gaap accepted,3.7651515151515147
1090,transition relief,3.764705882352941
1091,jersey,3.764516129032258
1092,aratana therapeutics,3.7636363636363637
1093,enables aratana,3.7636363636363637
1094,study,3.76078431372549
1095,considered substantive,3.7581521739130435
1096,action,3.757142857142857
1097,connor,3.7550807712350185
1098,predetermined safety,3.752688172043011
1099,contingent asset,3.75
1100,state nols,3.75
1101,manufacturing capability,3.75
1102,symptomatic treatment,3.7450980392156863
1103,neoadjuvant treatment,3.7450980392156863
1104,death,3.7407407407407405
1105,active enrollment,3.7406015037593985
1106,dos,3.737556561085973
1107,unusual nature,3.736842105263158
1108,heterogeneous nature,3.736842105263158
1109,research collaboration,3.736026111791106
1110,patient population,3.733904109589041
1111,authoritative guidance,3.7333333333333334
1112,guidance,3.7333333333333334
1113,guidance,3.7333333333333334
1114,ind filing,3.7316017316017316
1115,active market,3.7304147465437785
1116,potential inclusion,3.72972972972973
1117,substantive process,3.729166666666667
1118,increased headcount,3.7263157894736842
1119,milestone event,3.7199999999999998
1120,study,3.7153297682709447
1121,table,3.7140350877192985
1122,standard recognition,3.712025316455696
1123,amortization expense,3.7102564102564104
1124,major source,3.7058823529411766
1125,gross proceeds,3.7058823529411766
1126,proceeds,3.7058823529411766
1127,finance,3.7037037037037037
1128,material impact,3.7
1129,preclinical study,3.69828431372549
1130,considered remote,3.6956521739130435
1131,statements,3.6807017543859653
1132,mine collaboration,3.6798245614035086
1133,increase significantly,3.6785276073619633
1134,study cohort,3.677450980392157
1135,aggregate amount,3.6734615384615386
1136,company,3.670225013082156
1137,bono action,3.669230769230769
1138,licensee possessing,3.666666666666667
1139,pet dog,3.666666666666667
1140,amputation,3.666666666666667
1141,amount,3.6634615384615383
1142,collaboration guidance,3.663157894736842
1143,integral part,3.6621621621621623
1144,support payments,3.6621621621621623
1145,amount,3.6542022792022792
1146,loss,3.6527777777777777
1147,immunologic adjuvant,3.6489028213166144
1148,march,3.6470588235294117
1149,march issue,3.6470588235294117
1150,expected period,3.6426193118756935
1151,epitope,3.6413793103448273
1152,development revenue,3.640526030041624
1153,service,3.634920634920635
1154,service,3.634920634920635
1155,professional service,3.634920634920635
1156,expansion cohort,3.625
1157,march,3.623249299719888
1158,office expense,3.623076923076923
1159,vested rsus,3.619047619047619
1160,sufficient understanding,3.6153846153846154
1161,executive employee,3.6142369991474848
1162,safety report,3.6137992831541217
1163,forfeited award,3.6103896103896105
1164,revenue recognition,3.6095041322314048
1165,regulatory registration,3.607142857142857
1166,final result,3.606470588235294
1167,employee,3.6045751633986924
1168,intellectual property,3.6
1169,equipment property,3.6
1170,contractual obligations,3.6
1171,america gaap,3.583333333333333
1172,gaap involves,3.583333333333333
1173,excellence results,3.5777777777777775
1174,royalty,3.5761904761904764
1175,measure fair,3.5698672911787668
1176,estimate reclassifications,3.5666666666666664
1177,osteosarcoma,3.5655430711610485
1178,development expense,3.557944974733296
1179,amount,3.5563186813186816
1180,fda notified,3.5555555555555554
1181,granted aratana,3.5553030303030306
1182,protocol amendment,3.553763440860215
1183,study,3.5502579979360167
1184,employee director,3.549019607843137
1185,update clarify,3.5454545454545454
1186,future forward,3.5438596491228074
1187,estimate,3.5428571428571427
1188,development milestone,3.541021897810219
1189,company,3.5368916797488223
1190,company,3.5368916797488223
1191,company,3.5368916797488223
1192,company,3.5368916797488223
1193,company,3.5368916797488223
1194,company,3.5368916797488223
1195,company,3.5368916797488223
1196,company,3.5368916797488223
1197,company,3.5368916797488223
1198,company,3.5368916797488223
1199,company doe,3.5368916797488223
1200,company,3.5368916797488223
1201,company,3.5368916797488223
1202,established based,3.5317460317460316
1203,presentation basis,3.5292397660818713
1204,management,3.5272525027808674
1205,entity,3.5238095238095237
1206,unconsolidated entity,3.5238095238095237
1207,company,3.513635865795334
1208,partner amgen,3.5135135135135136
1209,royalty amount,3.513461538461539
1210,agreement advaxis,3.5067448680351907
1211,time employee,3.5055413469735717
1212,reviewed individually,3.5
1213,court,3.5
1214,differ materially,3.5
1215,face interaction,3.5
1216,completed allowing,3.5
1217,brown university,3.5
1218,active development,3.4953076120959334
1219,pay million,3.4914529914529915
1220,company,3.4914371342942774
1221,united stated,3.4871794871794872
1222,aggregate intrinsic,3.482222222222222
1223,patient,3.480116230801162
1224,modest increase,3.478527607361963
1225,coverage,3.478527607361963
1226,company plan,3.475916069992725
1227,adxs,3.474806201550388
1228,expansion study,3.469117647058823
1229,trading day,3.4615384615384617
1230,protocol analysis,3.4466666666666663
1231,effective date,3.4466216216216217
1232,considered observable,3.4456521739130435
1233,unique mutation,3.4434782608695653
1234,immunologic effect,3.4343434343434343
1235,adjuvant axal,3.431573275862069
1236,part study,3.4229464758876524
1237,fundamental transaction,3.4210526315789473
1238,orderly transaction,3.4210526315789473
1239,persuasive evidence,3.416666666666667
1240,customers,3.416666666666667
1241,lease amendment,3.4165085388994307
1242,development service,3.415942532730854
1243,study,3.407843137254902
1244,reported aes,3.4074074074074074
1245,newly diagnosed,3.40625
1246,operation estimates,3.4054054054054053
1247,operation,3.4054054054054053
1248,operation milestones,3.4054054054054053
1249,care treatment,3.395098039215686
1250,principal market,3.3911290322580645
1251,continues conducting,3.375
1252,company,3.370225013082156
1253,reasonable expectation,3.36231884057971
1254,change materially,3.361111111111111
1255,material change,3.361111111111111
1256,development grant,3.3599692662312717
1257,topic revenue,3.3595041322314048
1258,patient recruitment,3.358904109589041
1259,patient surveillance,3.358904109589041
1260,individual patient,3.358904109589041
1261,patient,3.358904109589041
1262,tnbc patient,3.358904109589041
1263,accruing patient,3.358904109589041
1264,patient consenting,3.358904109589041
1265,greater immunogenicity,3.3571428571428568
1266,item management,3.354838709677419
1267,previous finding,3.3529411764705883
1268,durvalumab medi,3.35
1269,committee,3.337152209492635
1270,sellas,3.333333333333333
1271,estimated impact,3.331578947368421
1272,company,3.3226059654631084
1273,care amputation,3.3166666666666664
1274,study,3.302450980392157
1275,december patient,3.294387980556783
1276,reduce overhead,3.2941176470588234
1277,chancery,3.2867383512544803
1278,relative fair,3.284153005464481
1279,fair values,3.284153005464481
1280,assumption,3.2835249042145596
1281,combination treatment,3.2784313725490195
1282,company,3.2776324204895633
1283,instrument,3.27536231884058
1284,young woman,3.2682926829268295
1285,indian woman,3.2682926829268295
1286,animal,3.2636363636363637
1287,result,3.263333333333333
1288,million woman,3.259745674379821
1289,september issue,3.25
1290,axal,3.244791666666667
1291,percent improvement,3.2447552447552446
1292,recognize revenue,3.24411951684679
1293,implementation guidance,3.2333333333333334
1294,operating purpose,3.2333333333333334
1295,company,3.2325438536618663
1296,nonrefundable achievement,3.230769230769231
1297,inherently subject,3.2285714285714286
1298,commercialization partner,3.2241379310344827
1299,major component,3.2058823529411766
1300,date,3.200568990042674
1301,limited availability,3.2
1302,placebo,3.2
1303,study,3.19828431372549
1304,quality safety,3.197132616487455
1305,personal fund,3.1904761904761907
1306,al case,3.1833333333333336
1307,market access,3.182795698924731
1308,revenue,3.177685950413223
1309,patient adxs,3.167043644472762
1310,medimmune llc,3.166666666666667
1311,replace today,3.166666666666667
1312,company belief,3.152276295133438
1313,transition method,3.139705882352941
1314,planned investigation,3.1372549019607847
1315,differ substantially,3.125
1316,stage,3.1197429906542054
1317,sale,3.118279569892473
1318,addition fluctuation,3.1132075471698113
1319,company,3.103558346415489
1320,pennsylvania penn,3.0994152046783627
1321,increase,3.0939122227465785
1322,inception,3.0938375350140057
1323,dismiss specifically,3.090909090909091
1324,patient,3.0896733403582717
1325,time,3.0815217391304346
1326,revenue,3.076895436579231
1327,specific amendment,3.071307300509338
1328,commercialization agreement,3.069592476489028
1329,difference estimate,3.0666666666666664
1330,fixed number,3.0609756097560976
1331,small number,3.0609756097560976
1332,legal proceeding,3.060846560846561
1333,fair statement,3.0501104522729916
1334,total fair,3.0488588878174223
1335,stage,3.0411471002432466
1336,company,3.0368916797488223
1337,adopting asu,3.0238095238095237
1338,operations advaxis,3.006117908787542
1339,patient treated,3.005962933118453
1340,axal support,2.9902871621621623
1341,axal advaxis,2.989415322580645
1342,commercialization milestone,2.984137931034483
1343,axal due,2.970982142857143
1344,safety,2.9526881720430107
1345,company review,2.9486563856311756
1346,prejudice bono,2.935897435897436
1347,assured royalty,2.918181818181818
1348,aggregate consideration,2.913846153846154
1349,dose,2.8529411764705883
1350,time,2.8315217391304346
1351,company,2.8163034444547046
1352,higher,2.813953488372093
1353,entity,2.8095238095238093
1354,company,2.797761244966214
1355,company,2.7868916797488223
1356,company,2.7868916797488223
1357,progression,2.7777777777777777
1358,veterinary medicine,2.7666666666666666
1359,settlement,2.764705882352941
1360,company,2.7542829840966485
1361,record allowance,2.7142857142857144
1362,attributable,2.7142857142857144
1363,order,2.6923076923076925
1364,level,2.6785714285714284
1365,pursuant,2.6666666666666665
1366,month,2.658307210031348
1367,party,2.6544117647058822
1368,tax,2.6493506493506493
1369,stock,2.597826086956522
1370,cfu dos,2.5968436154949783
1371,enroll patient,2.581126331811263
1372,advanced,2.5555555555555554
1373,rate,2.5555555555555554
1374,beginning,2.53125
1375,significant,2.5277777777777777
1376,positive,2.526315789473684
1377,clinical,2.52046783625731
1378,patient achieving,2.501761252446184
1379,disease,2.5
1380,investigator,2.5
1381,hypotension,2.5
1382,equity,2.4696969696969697
1383,provide,2.466666666666667
1384,common,2.4451219512195124
1385,claim,2.4358974358974357
1386,licensure,2.4285714285714284
1387,address,2.4285714285714284
1388,probable,2.4285714285714284
1389,intangible,2.4242424242424243
1390,trial,2.408695652173913
1391,response,2.4035087719298245
1392,model,2.4
1393,cat,2.4
1394,july,2.388157894736842
1395,generally,2.3846153846153846
1396,objective,2.3703703703703702
1397,investigational,2.3684210526315788
1398,existing,2.3636363636363638
1399,obligation,2.3529411764705883
1400,cash,2.3430232558139537
1401,achieved,2.3333333333333335
1402,phase,2.3222222222222224
1403,including,2.3157894736842106
1404,human,2.3157894736842106
1405,accounting,2.310344827586207
1406,april,2.2865853658536586
1407,targeted,2.2857142857142856
1408,price,2.275
1409,normal,2.272727272727273
1410,failed,2.272727272727273
1411,adoption,2.269230769230769
1412,ongoing,2.269230769230769
1413,option,2.2666666666666666
1414,related,2.2666666666666666
1415,directly,2.25
1416,achieve,2.25
1417,cancer,2.247148288973384
1418,make,2.230769230769231
1419,cost,2.2280701754385963
1420,earned,2.227272727272727
1421,criterion,2.2222222222222223
1422,provision,2.2142857142857144
1423,metastatic,2.212121212121212
1424,future,2.210526315789474
1425,grade,2.210526315789474
1426,chemotherapy,2.210526315789474
1427,payment,2.2045454545454546
1428,world,2.2
1429,chemoradiation,2.2
1430,agent,2.2
1431,mild,2.2
1432,application,2.1951219512195124
1433,public,2.1923076923076925
1434,gog,2.189189189189189
1435,accepted,2.1818181818181817
1436,advancement,2.176470588235294
1437,requires,2.1724137931034484
1438,complete,2.1714285714285713
1439,tumor,2.1666666666666665
1440,general,2.1607142857142856
1441,opportunity,2.1578947368421053
1442,loss,2.1527777777777777
1443,survival,2.1486486486486487
1444,disclosure,2.1481481481481484
1445,warrant,2.1440677966101696
1446,construct,2.142857142857143
1447,long,2.142857142857143
1448,purchase,2.142857142857143
1449,fever,2.142857142857143
1450,equivalent,2.1379310344827585
1451,expenses,2.1379310344827585
1452,commitment,2.125
1453,experienced,2.121212121212121
1454,offset,2.1153846153846154
1455,period,2.1132075471698113
1456,timing,2.111111111111111
1457,sae,2.111111111111111
1458,regulatory,2.107142857142857
1459,committee,2.106382978723404
1460,drug,2.1052631578947367
1461,license,2.103448275862069
1462,adequate,2.1
1463,presented,2.096774193548387
1464,neck,2.08
1465,year,2.0779220779220777
1466,required,2.076923076923077
1467,risk,2.0727272727272728
1468,issued,2.064516129032258
1469,substantive,2.0625
1470,employee,2.049019607843137
1471,share,2.047808764940239
1472,spending,2.0476190476190474
1473,mutation,2.0434782608695654
1474,january,2.0428571428571427
1475,licensing,2.04
1476,lease,2.0294117647058822
1477,enrollment,2.026315789473684
1478,market,2.0161290322580645
1479,funded,2.0
1480,information,2.0
1481,received,2.0
1482,recorded,2.0
1483,warrants,2.0
1484,served,2.0
1485,court,2.0
1486,rent,2.0
1487,laboratory,2.0
1488,maa,2.0
1489,caused,2.0
1490,cytotoxic,2.0
1491,tme,2.0
1492,clinically,2.0
1493,raised,2.0
1494,material,2.0
1495,note,2.0
1496,arrangement,2.0
1497,accrual,2.0
1498,dtllo,2.0
1499,million,1.9914529914529915
1500,product,1.9875
1501,investment,1.9855072463768115
1502,target,1.981818181818182
1503,business,1.98
1504,account,1.9767441860465116
1505,based,1.9761904761904763
1506,basis,1.9736842105263157
1507,liability,1.972972972972973
1508,data,1.9642857142857142
1509,standard,1.9620253164556962
1510,cell,1.9603960396039604
1511,event,1.96
1512,determined,1.9545454545454546
1513,stendhal,1.9523809523809523
1514,asset,1.95
1515,society,1.95
1516,technology,1.9473684210526316
1517,set,1.9473684210526316
1518,approximately,1.9417989417989419
1519,bsm,1.9411764705882353
1520,plan,1.9390243902439024
1521,preclinical,1.9375
1522,december,1.935483870967742
1523,defendant,1.935483870967742
1524,amortization,1.9333333333333333
1525,collaboration,1.9298245614035088
1526,cohort,1.9166666666666667
1527,amount,1.9134615384615385
1528,successful,1.9090909090909092
1529,immunotherapy,1.907216494845361
1530,commitments,1.9
1531,action,1.9
1532,osteosarcoma,1.898876404494382
1533,receive,1.891304347826087
1534,effect,1.8888888888888888
1535,conversion,1.8888888888888888
1536,consistent,1.8888888888888888
1537,infection,1.8888888888888888
1538,base,1.8888888888888888
1539,impairment,1.8888888888888888
1540,compared,1.8888888888888888
1541,merck,1.8857142857142857
1542,fiscal,1.8823529411764706
1543,obtain,1.875
1544,approval,1.8666666666666667
1545,report,1.8611111111111112
1546,revenue,1.859504132231405
1547,include,1.8571428571428572
1548,meeting,1.8571428571428572
1549,office,1.8461538461538463
1550,agreement,1.8454545454545455
1551,initiated,1.8333333333333333
1552,continues,1.8333333333333333
1553,effective,1.825
1554,therapy,1.8235294117647058
1555,adxs,1.808139534883721
1556,research,1.806201550387597
1557,type,1.8
1558,results,1.8
1559,prevent,1.8
1560,contingent,1.8
1561,granted,1.7916666666666667
1562,conducted,1.7894736842105263
1563,paid,1.7857142857142858
1564,term,1.7826086956521738
1565,development,1.781021897810219
1566,delaware,1.7777777777777777
1567,incurred,1.7777777777777777
1568,excellence,1.7777777777777777
1569,participant,1.7777777777777777
1570,expense,1.7769230769230768
1571,factor,1.7741935483870968
1572,bono,1.7692307692307692
1573,outcome,1.7692307692307692
1574,accounted,1.7692307692307692
1575,hold,1.7666666666666666
1576,table,1.7666666666666666
1577,statement,1.7659574468085106
1578,total,1.7647058823529411
1579,transition,1.7647058823529411
1580,aratana,1.7636363636363637
1581,vested,1.7619047619047619
1582,study,1.7607843137254902
1583,aggregate,1.76
1584,milestone,1.76
1585,safety,1.7526881720430108
1586,manufacturing,1.75
1587,carrying,1.75
1588,recognition,1.75
1589,state,1.75
1590,observable,1.75
1591,virus,1.75
1592,mine,1.75
1593,treatment,1.7450980392156863
1594,reported,1.7407407407407407
1595,condition,1.7407407407407407
1596,nature,1.736842105263158
1597,statements,1.7333333333333334
1598,guidance,1.7333333333333334
1599,recurrence,1.7333333333333334
1600,enrolled,1.7307692307692308
1601,potential,1.7297297297297298
1602,intrinsic,1.7222222222222223
1603,follow,1.7222222222222223
1604,head,1.7209302325581395
1605,elected,1.7142857142857142
1606,active,1.7142857142857142
1607,scchn,1.7142857142857142
1608,expansion,1.7083333333333333
1609,major,1.7058823529411764
1610,proceeds,1.7058823529411764
1611,legal,1.7037037037037037
1612,antigen,1.7
1613,impact,1.7
1614,quarter,1.7
1615,jersey,1.7
1616,reasonable,1.6956521739130435
1617,motion,1.6956521739130435
1618,considered,1.6956521739130435
1619,specific,1.6842105263157894
1620,exchange,1.6842105263157894
1621,stage,1.6822429906542056
1622,regulation,1.6666666666666667
1623,licensee,1.6666666666666667
1624,measured,1.6666666666666667
1625,process,1.6666666666666667
1626,summary,1.6666666666666667
1627,pursue,1.6666666666666667
1628,issuance,1.6666666666666667
1629,present,1.6666666666666667
1630,complaint,1.6666666666666667
1631,section,1.6666666666666667
1632,expectation,1.6666666666666667
1633,lts,1.6666666666666667
1634,step,1.6666666666666667
1635,includes,1.6666666666666667
1636,planned,1.6666666666666667
1637,dog,1.6666666666666667
1638,amputation,1.6666666666666667
1639,suggest,1.6666666666666667
1640,commercialize,1.6666666666666667
1641,experience,1.6666666666666667
1642,show,1.6666666666666667
1643,vest,1.6666666666666667
1644,shared,1.6666666666666667
1645,vaccination,1.6666666666666667
1646,minimum,1.6666666666666667
1647,replace,1.6666666666666667
1648,aes,1.6666666666666667
1649,part,1.662162162162162
1650,support,1.662162162162162
1651,advaxis,1.6612903225806452
1652,care,1.65
1653,march,1.6470588235294117
1654,showed,1.6470588235294117
1655,treated,1.6470588235294117
1656,due,1.6428571428571428
1657,service,1.6349206349206349
1658,estimated,1.631578947368421
1659,substantially,1.625
1660,involved,1.625
1661,date,1.6216216216216217
1662,sufficient,1.6153846153846154
1663,belief,1.6153846153846154
1664,resulted,1.6153846153846154
1665,award,1.6103896103896105
1666,instrument,1.608695652173913
1667,hpv,1.603305785123967
1668,royalty,1.6
1669,placebo,1.6
1670,administered,1.6
1671,systemic,1.6
1672,property,1.6
1673,moderate,1.6
1674,made,1.588235294117647
1675,gaap,1.5833333333333333
1676,grant,1.5789473684210527
1677,neoepitope,1.5714285714285714
1678,estimate,1.5666666666666667
1679,executive,1.565217391304348
1680,number,1.5609756097560976
1681,fda,1.5555555555555556
1682,included,1.5555555555555556
1683,presentation,1.5555555555555556
1684,established,1.5555555555555556
1685,update,1.5454545454545454
1686,immunologic,1.5454545454545454
1687,conducting,1.5416666666666667
1688,company,1.5368916797488226
1689,combination,1.5333333333333334
1690,expected,1.5294117647058822
1691,asu,1.5238095238095237
1692,entity,1.5238095238095237
1693,observed,1.5161290322580645
1694,amgen,1.5135135135135136
1695,asia,1.5
1696,fixed,1.5
1697,differ,1.5
1698,granting,1.5
1699,director,1.5
1700,implementation,1.5
1701,adopting,1.5
1702,eliminating,1.5
1703,university,1.5
1704,entitled,1.5
1705,waste,1.5
1706,dismissed,1.5
1707,individually,1.5
1708,completed,1.5
1709,face,1.5
1710,component,1.5
1711,small,1.5
1712,veterinary,1.5
1713,animal,1.5
1714,expect,1.5
1715,difference,1.5
1716,today,1.5
1717,identified,1.5
1718,registration,1.5
1719,performed,1.5
1720,topic,1.5
1721,pay,1.5
1722,portion,1.48
1723,increase,1.478527607361963
1724,permitted,1.4761904761904763
1725,investigation,1.4705882352941178
1726,needed,1.4615384615384615
1727,day,1.4615384615384615
1728,time,1.4565217391304348
1729,sale,1.4516129032258065
1730,quality,1.4444444444444444
1731,met,1.4375
1732,result,1.43
1733,end,1.4285714285714286
1734,occur,1.4285714285714286
1735,filing,1.4285714285714286
1736,anticipate,1.4285714285714286
1737,transaction,1.4210526315789473
1738,customers,1.4166666666666667
1739,evidence,1.4166666666666667
1740,efficacy,1.4126984126984128
1741,review,1.411764705882353
1742,diagnosed,1.40625
1743,operation,1.4054054054054055
1744,collectability,1.4
1745,country,1.4
1746,annually,1.4
1747,epitope,1.4
1748,unique,1.4
1749,obligations,1.4
1750,october,1.3978494623655915
1751,amendment,1.3870967741935485
1752,recognize,1.3846153846153846
1753,allowance,1.380952380952381
1754,excluded,1.375
1755,method,1.375
1756,principal,1.375
1757,party,1.375
1758,input,1.3636363636363635
1759,change,1.3611111111111112
1760,patient,1.358904109589041
1761,proceeding,1.3571428571428572
1762,management,1.3548387096774193
1763,dos,1.3529411764705883
1764,finding,1.3529411764705883
1765,durvalumab,1.35
1766,india,1.3478260869565217
1767,operations,1.3448275862068966
1768,evaluated,1.34375
1769,work,1.3333333333333333
1770,november,1.3333333333333333
1771,forward,1.3333333333333333
1772,tolerated,1.3333333333333333
1773,record,1.3333333333333333
1774,listeria,1.3333333333333333
1775,sellas,1.3333333333333333
1776,axal,1.328125
1777,assured,1.3181818181818181
1778,developed,1.3076923076923077
1779,stated,1.3076923076923077
1780,reduce,1.2941176470588236
1781,assist,1.2857142857142858
1782,sublicense,1.2857142857142858
1783,fair,1.284153005464481
1784,analysis,1.28
1785,entered,1.2794117647058822
1786,evaluating,1.2758620689655173
1787,woman,1.2682926829268293
1788,medicine,1.2666666666666666
1789,filed,1.2608695652173914
1790,settled,1.25
1791,september,1.25
1792,franchise,1.25
1793,reached,1.25
1794,spa,1.25
1795,cfu,1.2439024390243902
1796,responsible,1.2307692307692308
1797,achievement,1.2307692307692308
1798,subject,1.2285714285714286
1799,commercialization,1.2241379310344827
1800,persistent,1.2222222222222223
1801,chancery,1.2222222222222223
1802,enroll,1.2222222222222223
1803,recognized,1.2173913043478262
1804,immunogenicity,1.2142857142857142
1805,penn,1.2105263157894737
1806,connor,1.2105263157894737
1807,gbp,1.2
1808,limited,1.2
1809,purpose,1.2
1810,evaluate,1.2
1811,headcount,1.2
1812,order,1.1923076923076923
1813,fund,1.1904761904761905
1814,case,1.1833333333333333
1815,purchased,1.1818181818181819
1816,august,1.1785714285714286
1817,access,1.1666666666666667
1818,prejudice,1.1666666666666667
1819,medimmune,1.1666666666666667
1820,men,1.1666666666666667
1821,selected,1.1666666666666667
1822,classified,1.1666666666666667
1823,consideration,1.1538461538461537
1824,decrease,1.1538461538461537
1825,percent,1.1538461538461537
1826,inds,1.1428571428571428
1827,achieving,1.1428571428571428
1828,file,1.1428571428571428
1829,monotherapy,1.1304347826086956
1830,inception,1.1176470588235294
1831,addition,1.1132075471698113
1832,assumption,1.1111111111111112
1833,dismiss,1.0909090909090908
1834,dna,1.0833333333333333
1835,february,1.0740740740740742
1836,notes,1.0
1837,believed,1.0
1838,activate,1.0
1839,enable,1.0
1840,proceed,1.0
1841,advance,1.0
1842,ema,1.0
1843,develop,1.0
1844,usda,1.0
1845,area,1.0
1846,put,1.0
1847,submission,1.0
1848,discussion,1.0
1849,accordance,1.0
1850,recommendation,1.0
1851,implement,1.0
1852,lifted,1.0
1853,respect,1.0
1854,establishing,1.0
1855,incorporates,1.0
1856,commercialized,1.0
1857,invest,1.0
1858,exploration,1.0
1859,expanding,1.0
1860,developing,1.0
1861,continue,1.0
1862,prove,1.0
1863,wrong,1.0
1864,uncertainty,1.0
1865,unable,1.0
1866,completing,1.0
1867,execute,1.0
1868,assurance,1.0
1869,profitable,1.0
1870,prepared,1.0
1871,rule,1.0
1872,sec,1.0
1873,form,1.0
1874,opinion,1.0
1875,represent,1.0
1876,read,1.0
1877,conjunction,1.0
1878,derived,1.0
1879,derive,1.0
1880,majority,1.0
1881,controlled,1.0
1882,perpetual,1.0
1883,defined,1.0
1884,renew,1.0
1885,charged,1.0
1886,collection,1.0
1887,exhausted,1.0
1888,recovery,1.0
1889,preparation,1.0
1890,affect,1.0
1891,recoverability,1.0
1892,reclassified,1.0
1893,conform,1.0
1894,reclassification,1.0
1895,maintained,1.0
1896,exposed,1.0
1897,computed,1.0
1898,computation,1.0
1899,consultant,1.0
1900,estimating,1.0
1901,judgment,1.0
1902,charge,1.0
1903,convergence,1.0
1904,contracts,1.0
1905,good,1.0
1906,reflects,1.0
1907,adopted,1.0
1908,defers,1.0
1909,clarifies,1.0
1910,amend,1.0
1911,aspect,1.0
1912,utilize,1.0
1913,simplify,1.0
1914,subtopic,1.0
1915,concept,1.0
1916,distinguished,1.0
1917,infrequency,1.0
1918,deleted,1.0
1919,applied,1.0
1920,outlined,1.0
1921,investments,1.0
1922,passed,1.0
1923,expiration,1.0
1924,abandoned,1.0
1925,determination,1.0
1926,expired,1.0
1927,aggregated,1.0
1928,calculate,1.0
1929,gain,1.0
1930,determining,1.0
1931,exercised,1.0
1932,daniel,1.0
1933,sara,1.0
1934,secretary,1.0
1935,executives,1.0
1936,directors,1.0
1937,board,1.0
1938,consultants,1.0
1939,delivered,1.0
1940,existence,1.0
1941,knoll,1.0
1942,breach,1.0
1943,answer,1.0
1944,defend,1.0
1945,officer,1.0
1946,behalf,1.0
1947,named,1.0
1948,district,1.0
1949,aug,1.0
1950,violation,1.0
1951,member,1.0
1952,denying,1.0
1953,express,1.0
1954,ordinary,1.0
1955,duration,1.0
1956,cover,1.0
1957,manage,1.0
1958,located,1.0
1959,scheduled,1.0
1960,expire,1.0
1961,increment,1.0
1962,remainder,1.0
1963,transfer,1.0
1964,buyer,1.0
1965,seller,1.0
1966,transact,1.0
1967,unobservable,1.0
1968,indirectly,1.0
1969,corroborated,1.0
1970,supported,1.0
1971,happen,1.0
1972,incorporated,1.0
1973,reference,1.0
1974,designed,1.0
1975,protect,1.0
1976,infected,1.0
1977,compliance,1.0
1978,vaccinated,1.0
1979,alive,1.0
1980,evaluable,1.0
1981,resolved,1.0
1982,incorporate,1.0
1983,initiate,1.0
1984,integrity,1.0
1985,field,1.0
1986,territory,1.0
1987,recur,1.0
1988,goal,1.0
1989,proof,1.0
1990,astrazeneca,1.0
1991,cervix,1.0
1992,sponsorship,1.0
1993,evaluation,1.0
1994,morbidity,1.0
1995,larynx,1.0
1996,reduction,1.0
1997,mip,1.0
1998,activated,1.0
1999,migration,1.0
2000,collaborate,1.0
2001,linked,1.0
2002,foregoing,1.0
2003,conduct,1.0
2004,leading,1.0
2005,important,1.0
2006,prevalence,1.0
2007,planning,1.0
2008,nsclc,1.0
2009,man,1.0
2010,lifetime,1.0
2011,die,1.0
2012,overexpressed,1.0
2013,percentage,1.0
2014,invasive,1.0
2015,intend,1.0
2016,child,1.0
2017,teen,1.0
2018,qualify,1.0
2019,affecting,1.0
2020,roughly,1.0
2021,lameness,1.0
2022,diagnosis,1.0
2023,ten,1.0
2024,analgesic,1.0
2025,direction,1.0
2026,determine,1.0
2027,safe,1.0
2028,delay,1.0
2029,unsuitable,1.0
2030,focus,1.0
2031,learning,1.0
2032,identify,1.0
2033,amenable,1.0
2034,receptor,1.0
2035,presence,1.0
2036,resistance,1.0
2037,attractive,1.0
2038,academic,1.0
2039,center,1.0
2040,expensed,1.0
2041,strategic,1.0
2042,distribute,1.0
2043,held,1.0
2044,inducing,1.0
2045,noteholders,1.0
2046,convert,1.0
2047,discount,1.0
2048,receipt,1.0
2049,calculation,1.0
2050,connection,1.0
2051,excess,1.0
2052,ability,1.0
2053,impose,1.0
2054,partnership,1.0
2055,begin,1.0
2056,operate,1.0
2057,cleanroom,1.0
2058,enter,1.0
2059,vendor,1.0
2060,cancelable,1.0
2061,obligated,1.0
2062,payable,1.0
2063,estimable,1.0
2064,expose,1.0
2065,engages,1.0
2066,critical,1.0
2067,uncertain,1.0
2068,discus,1.0
2069,designated,1.0
2070,june,1.0
2071,aren,1.0
2072,simplifies,1.0
2073,loan,1.0
2074,activates,1.0
2075,respond,1.0
2076,advancing,1.0
2077,worth,1.0
2078,week,1.0
2079,exploit,1.0
2080,europe,1.0
2081,comparing,1.0
2082,leveraging,1.0
2083,exploring,1.0
2084,continuing,1.0
2085,build,1.0
2086,deferred,1.0
2087,collectible,1.0
2088,relation,1.0
2089,priced,1.0
2090,reconsideration,1.0
2091,suitable,1.0
2092,compare,1.0
2093,frequency,1.0
2094,severity,1.0
2095,robust,1.0
2096,comparator,1.0
2097,progress,1.0
2098,assessing,1.0
2099,atmps,1.0
2100,underway,1.0
2101,agree,1.0
2102,budget,1.0
2103,understand,1.0
2104,presenting,1.0
2105,stimulating,1.0
2106,shelf,1.0
2107,ready,1.0
2108,administer,1.0
2109,explore,1.0
2110,carrier,1.0
2111,categorized,1.0
2112,contingencies,1.0
2113,fact,1.0
2114,reevaluates,1.0
2115,role,1.0
2116,endeavor,1.0
2117,guarantee,1.0
2118,technological,1.0
2119,improvements,1.0
2120,definition,1.0
2121,acquisition,1.0
2122,disposal,1.0
2123,screen,1.0
2124,remove,1.0
2125,diversity,1.0
2126,practice,1.0
2127,complexity,1.0
2128,applying,1.0
2129,counted,1.0
2130,scope,1.0
2131,receivables,1.0
2132,lieu,1.0
2133,matter,1.0
2134,insurance,1.0
2135,admission,1.0
2136,wrongdoing,1.0
2137,solely,1.0
2138,avoiding,1.0
2139,litigation,1.0
2140,resolution,1.0
2141,stipulation,1.0
2142,dismissal,1.0
2143,petit,1.0
2144,principle,1.0
2145,negotiating,1.0
2146,bms,1.0
2147,indicating,1.0
2148,secretes,1.0
2149,building,1.0
2150,bear,1.0
2151,sponsor,1.0
2152,half,1.0
